• We offer tailored partnerships to support and transform drug discovery.

    Every collaboration is a bespoke arrangement, meticulously designed to discover new compounds and targets in patient relevant disease models.

  • MIMETAS offers flexible fee-for-service solutions for therapy prioritization, optimization, and de-risking of compounds.

    As an extension of your team, MIMETAS provides the expertise and resources needed for effective research and development.

  • Our OrganoReady program is made for you when you need optimized assays for investigational toxicology.

    We guarantee OrganoReady performance according to specifications, in a fast and convenient sales transaction with a clear fee structure.

  • Giving you some food for thought. Read our blogs to learn more about 3D tissue culture, research backgrounds, developments, and its future outlook.
  • Get inspired by research done by our scientists, partners, and customers around the globe.

  • Learn about our mission, vision, the history of the company, and find out what we mean with MIMETAS-do.
open menu icon close menu icon
EN

MIMETAS attends AACR 2022 Conference in New Orleans

New Orleans, April 8-13, 2022 – MIMETAS has just attended the AACR Annual Meeting in person. The AACR Annual Meeting is organized by the American Association For Cancer Research (AACR).

This year’s program covered the latest discoveries across the spectrum of cancer research—from population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy—and highlights the work of the best minds in research and medicine from institutions all over the world. We would like to take you along in our activities and give a glimpse of this wonderful week!

MIMETAS at AACR 2022
Organ-on-a-chip (OoaC) models improve the human physiological relevance of cultured tissues and have better predictive ability than conventional models for drug screening. Making OoaC systems such as the OrganoPlate® platform available for automation and high-throughput drug screening purposes would offer the scalability and usability needed for pharmaceutical use. This will help make strides in accelerating oncology drug development and contribute to understanding the pathophysiology of (cancer) disease.

This year, MIMETAS attended with a booth and presented various posters addressing the use of Organ-on-a-Chip for cancer research. Attendees could delve into the latest advancements in our ground-breaking tissue and disease models enhancing oncology drug discovery and development.

Research presented at AACR:

Oncology related publications:


Do you want to learn more how we can support your cancer research? Get in touch with us!


Contact us Sign up for our Newsletter

Cookies

May we use cookies?
Hi there! Thanks for visiting our website. We use cookies to keep track of our website statistics to optimize the user experience. We also use cookies for marketing purposes. You can set your preferences by selecting the options below. Terms of Use & Privacy Policy
Accept all
Accept selected
Decline all